Ziresovir's Phase III results mark a significant milestone, representing the first clinical validation of an antiviral's ...

Protection against RSV among infants and birthing parents differed by race and ethnicity, indicating the need to ensure equitable access to RSV products.

Ziresovir is the first antiviral to demonstrate significant clinical efficacy and long-term respiratory benefits in ...

The Lancet Child & Adolescent Health, a leading international journal in pediatric and adolescent medicine, has published the ...

Coinfection with RSV, REV, and MPV was significantly associated with treatment failure and prolonged treatment in children with viral LRTIs on respiratory support.

This year’s World Health Day centres around improving maternal and newborn health, and kickstarts a year-long campaign from ...

A new antibody shot could help infants who contract respiratory ... significant lasting difference in what RSV, how it impacts our community." The treatment is also recommended for older adults ...

RSV is a common contagious virus characterised by several mild, cold-like symptoms. Although most people can recover within a week or two, the virus can cause severe illness in certain groups, ...

The market is driven by the rising awareness of RSV-related complications, advancements in antiviral treatments, and the development of monoclonal antibodies and vaccines. Pharmaceutical companies ...

Most treatments are supportive ... RSV disease Pregnant women during weeks 32-36 of pregnancy Infants can be protected from RSV early in life with an RSV antibody given soon after they're born.

If you’re feeling under the weather, chances are pretty high that you have one of four popular viruses going around: influenza A (the flu), COVID-19, norovirus (the stomach flu) and respiratory ...